AU2006223161B2 - Controlled release formulations of octreotide - Google Patents

Controlled release formulations of octreotide Download PDF

Info

Publication number
AU2006223161B2
AU2006223161B2 AU2006223161A AU2006223161A AU2006223161B2 AU 2006223161 B2 AU2006223161 B2 AU 2006223161B2 AU 2006223161 A AU2006223161 A AU 2006223161A AU 2006223161 A AU2006223161 A AU 2006223161A AU 2006223161 B2 AU2006223161 B2 AU 2006223161B2
Authority
AU
Australia
Prior art keywords
octreotide
implant
formulation
months
hydrogel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006223161A
Other languages
English (en)
Other versions
AU2006223161A1 (en
Inventor
Stephanie Decker
Petr Kuzma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endo Pharmaceuticals Solutions Inc
Original Assignee
Endo Pharmaceuticals Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endo Pharmaceuticals Solutions Inc filed Critical Endo Pharmaceuticals Solutions Inc
Publication of AU2006223161A1 publication Critical patent/AU2006223161A1/en
Assigned to ENDO PHARMACEUTICALS SOLUTIONS INC. reassignment ENDO PHARMACEUTICALS SOLUTIONS INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: INDEVUS PHARMACEUTICALS, INC.
Priority to AU2011201457A priority Critical patent/AU2011201457B2/en
Priority to AU2011201460A priority patent/AU2011201460B2/en
Priority to AU2011201471A priority patent/AU2011201471B2/en
Application granted granted Critical
Publication of AU2006223161B2 publication Critical patent/AU2006223161B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2006223161A 2005-03-11 2006-03-10 Controlled release formulations of octreotide Ceased AU2006223161B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2011201457A AU2011201457B2 (en) 2005-03-11 2011-03-31 Controlled release formulations of octreotide
AU2011201460A AU2011201460B2 (en) 2005-03-11 2011-03-31 Controlled release formulations of octreotide
AU2011201471A AU2011201471B2 (en) 2005-03-11 2011-03-31 Controlled release formulations of octreotide

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66093005P 2005-03-11 2005-03-11
US60/660,930 2005-03-11
PCT/US2006/008891 WO2006099288A2 (en) 2005-03-11 2006-03-10 Controlled release formulations of octreotide

Related Child Applications (3)

Application Number Title Priority Date Filing Date
AU2011201457A Division AU2011201457B2 (en) 2005-03-11 2011-03-31 Controlled release formulations of octreotide
AU2011201460A Division AU2011201460B2 (en) 2005-03-11 2011-03-31 Controlled release formulations of octreotide
AU2011201471A Division AU2011201471B2 (en) 2005-03-11 2011-03-31 Controlled release formulations of octreotide

Publications (2)

Publication Number Publication Date
AU2006223161A1 AU2006223161A1 (en) 2006-09-21
AU2006223161B2 true AU2006223161B2 (en) 2011-05-12

Family

ID=36992335

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2006223161A Ceased AU2006223161B2 (en) 2005-03-11 2006-03-10 Controlled release formulations of octreotide
AU2011201471A Ceased AU2011201471B2 (en) 2005-03-11 2011-03-31 Controlled release formulations of octreotide
AU2011201457A Ceased AU2011201457B2 (en) 2005-03-11 2011-03-31 Controlled release formulations of octreotide
AU2011201460A Ceased AU2011201460B2 (en) 2005-03-11 2011-03-31 Controlled release formulations of octreotide

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2011201471A Ceased AU2011201471B2 (en) 2005-03-11 2011-03-31 Controlled release formulations of octreotide
AU2011201457A Ceased AU2011201457B2 (en) 2005-03-11 2011-03-31 Controlled release formulations of octreotide
AU2011201460A Ceased AU2011201460B2 (en) 2005-03-11 2011-03-31 Controlled release formulations of octreotide

Country Status (13)

Country Link
US (8) US7452868B2 (https=)
EP (3) EP2455072A1 (https=)
JP (2) JP4584331B2 (https=)
KR (1) KR101399911B1 (https=)
CN (2) CN101193626A (https=)
AU (4) AU2006223161B2 (https=)
CA (1) CA2601304C (https=)
EA (1) EA015793B1 (https=)
IL (2) IL185800A0 (https=)
NO (1) NO20074628L (https=)
NZ (1) NZ561400A (https=)
UA (1) UA89398C2 (https=)
WO (1) WO2006099288A2 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858110B2 (en) * 2003-08-11 2010-12-28 Endo Pharmaceuticals Solutions, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
EP1773293B1 (en) 2004-06-17 2015-04-15 Endo Pharmaceuticals Solutions Inc. Compositions and methods for treating central precocious puberty
AU2005316545A1 (en) * 2004-12-15 2006-06-22 Qlt Usa, Inc. Sustained delivery formulations of octreotide compounds
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
EP2455072A1 (en) * 2005-03-11 2012-05-23 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide
CA2620202C (en) 2005-08-26 2016-10-04 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
US20080286325A1 (en) * 2006-01-05 2008-11-20 Med Institute, Inc. Cyclodextrin elution media for medical device coatings comprising a taxane therapeutic agent
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
MX2009011641A (es) * 2007-04-27 2010-03-04 Endo Pharmaceuticals Solutions Agentes de liberacion para dispositivo de implante y metodos para utilizar los mismos.
WO2008143958A1 (en) * 2007-05-18 2008-11-27 The Brigham And Women's Hospital, Inc. Use of somatostatin analogs in myocardial perfusion imaging
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2009148583A2 (en) * 2008-06-03 2009-12-10 Qlt Usa, Inc. Method for improvement of octreotide bioavailability
US20090325863A1 (en) * 2008-06-13 2009-12-31 Kleinberg David L Somatostatin analogs and IGF-I inhibition for breast cancer prevention
WO2009158412A2 (en) 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
UA104866C2 (uk) * 2008-06-25 2014-03-25 Ендо Фармас'Ютікалз Солюшнз Інк. Імплантат октреотиду, який містить вивільняючу речовину
CN102176900B (zh) 2008-09-17 2017-09-26 克艾思马有限公司 药物组合物和相关的给药方法
US20110236456A1 (en) * 2008-09-30 2011-09-29 Endo Pharmaceuticals Solutions Inc. Implantable device for the delivery of histrelin and methods of use thereof
CA2739180C (en) * 2008-09-30 2017-12-19 Endo Pharmaceuticals Solutions Inc. Implantable device for the delivery of octreotide and methods of use thereof
CA2739181C (en) * 2008-09-30 2017-03-14 Endo Pharmaceuticals Solutions Inc. Implantable device for the delivery of risperidone and methods of use thereof
EP2498763A4 (en) 2009-11-09 2015-10-07 Spotlight Technology Partners Llc HYDROGELE ON POLYSACCHARIDBASIS
CN102695501A (zh) 2009-11-09 2012-09-26 聚光灯技术合伙有限责任公司 碎裂水凝胶
WO2012074559A2 (en) 2010-12-02 2012-06-07 New York University Treatment of non-proliferative cystic disease
JP6149183B2 (ja) 2011-10-24 2017-06-21 ブレイバーン ファーマシューティカルズ，インコーポレイティド 移植可能チザニジン組成物及びその治療方法
US20130183263A1 (en) 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US10646552B2 (en) 2012-01-17 2020-05-12 Tyme, Inc. Pharmaceutical compositions and methods
US8481498B1 (en) 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US10272068B2 (en) 2012-01-17 2019-04-30 Tyme, Inc. Pharmaceutical compositions and methods
EP3007704B1 (en) * 2013-06-13 2021-01-06 Antisense Therapeutics Ltd Combination therapy for acromegaly
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US10751313B2 (en) 2013-10-22 2020-08-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US9326962B2 (en) 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9763903B2 (en) 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
SG10201803370XA (en) 2013-10-22 2018-06-28 Prolynx Llc Conjugates of somatostatin and its analogs
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
SG11201705591PA (en) 2015-01-07 2017-08-30 Trigemina Inc Magnesium-containing oxytocin formulations and methods of use
HUE071943T2 (hu) 2015-02-03 2025-10-28 Amryt Endo Inc Akromegália kezelése oktreotid orális alkalmazásával
HUE070412T2 (hu) 2016-04-12 2025-06-28 Tonix Pharma Ltd Magnézium tartalmú oxitocin készítmények és alkamazási eljárásaik
WO2020018291A1 (en) 2018-07-19 2020-01-23 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
CN111214643A (zh) * 2020-03-11 2020-06-02 苏州善湾生物医药科技有限公司 一种基于皮下凝胶缓释的奥曲肽组合物、制备方法及应用
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
JP2025508846A (ja) * 2022-02-25 2025-04-10 アムリット・エンドゥ・インコーポレイテッド 疾患の治療のための経口オクトレオチド
EP4698205A1 (en) * 2023-03-27 2026-02-25 Cellular Longevity, Inc. Pharmaceutical formulations for longevity in mammals
WO2025097068A1 (en) * 2023-11-01 2025-05-08 Entrega Inc. Oral dosage form with ionically chargeable hydrogel for delivery of active agent and permeation enhancer
WO2026006394A1 (en) * 2024-06-26 2026-01-02 Loyal Animal Health, Inc. Somatostatin analogs and compositions and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876761A (en) * 1989-07-07 1999-03-02 Novartis Ag Sustained release formulations of water soluble peptides
WO2002049573A2 (en) * 2000-12-18 2002-06-27 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US71736A (en) * 1867-12-03 Improvement in fences
US2168331A (en) 1936-10-17 1939-08-08 Du Pont Cast resin with integral sheen
US2513014A (en) * 1946-11-18 1950-06-27 Abbott Lab Apparatus for implanting medicinal pellets subcutaneously
GB1306541A (en) 1969-01-20 1973-02-14 Ceskoslovenska Akademie Ved Method of manufacturing tubes by centrifugal casting
US3772435A (en) * 1971-11-02 1973-11-13 American Cyanamid Co Method of using steroid acetonides as growth promoting agents
US3975350A (en) * 1972-08-02 1976-08-17 Princeton Polymer Laboratories, Incorporated Hydrophilic or hydrogel carrier systems such as coatings, body implants and other articles
US3921632A (en) * 1974-08-16 1975-11-25 Frank M Bardani Implant device
US4131604A (en) 1977-11-23 1978-12-26 Thermo Electron Corporation Polyurethane elastomer for heart assist devices
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4298002A (en) * 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
US4386039A (en) 1980-02-11 1983-05-31 Thermo Electron Corporation Process for forming an optically clear polyurethane lens or cornea
US4523005A (en) 1981-10-30 1985-06-11 Thermedics, Inc. Extrudable polyurethane for prosthetic devices prepared from a diisocyanate, a polytetramethylene ether polyol, and 1,4-butane diol
US4751133A (en) 1984-11-13 1988-06-14 Thermedics, Inc. Medical patches and processes for producing same
US5342622A (en) * 1986-05-16 1994-08-30 The State Of Victoria Subdermal biocompatible implants
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4743673A (en) 1986-12-19 1988-05-10 Tyndale Plains-Hunter, Ltd. Hydrophilic carboxy polyurethanes
US4871094A (en) * 1986-12-31 1989-10-03 Alcon Laboratories, Inc. Means and method for dispensing substances
US4994028A (en) * 1987-03-18 1991-02-19 Endocon, Inc. Injector for inplanting multiple pellet medicaments
US4846793A (en) * 1987-03-18 1989-07-11 Endocon, Inc. Injector for implanting multiple pellet medicaments
AU608891B2 (en) 1987-09-24 1991-04-18 Merck & Co., Inc. Solubility modulated drug delivery device
US5035891A (en) * 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US4954587A (en) * 1988-07-05 1990-09-04 Ciba-Geigy Corporation Dimethylacrylamide-copolymer hydrogels with high oxygen permeability
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
DK0384646T3 (da) 1989-02-16 1993-07-12 British Tech Group Dispenseringsindretning
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5468811A (en) * 1989-11-02 1995-11-21 National Patent Development Corporation Hydrophilic composite polymer articles formed from a settable paste comprising a mixture of hydrophilic polymer and unsaturated monomer
US5254662A (en) 1990-09-12 1993-10-19 Polymedia Industries, Inc. Biostable polyurethane products
WO1992005775A1 (en) * 1990-09-28 1992-04-16 Pfizer Inc. Dispensing device containing a hydrophobic medium
US5266325A (en) 1990-09-28 1993-11-30 Hydro Med Science Division Of National Patent Development Corp. Preparation of homogeneous hydrogel copolymers
AU651654B2 (en) 1992-01-14 1994-07-28 Endo Pharmaceuticals Solutions Inc. Manufacture of water-swellable hydrophilic articles and drug delivery devices
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
AU652984B2 (en) 1992-01-14 1994-09-15 Endo Pharmaceuticals Solutions Inc. Preparation of homogeneous hydrogel copolymers
JP2530079B2 (ja) * 1992-02-05 1996-09-04 ナショナル・パテント・ディベロプメント・コーポレーション 水分膨潤性親水性製品及び薬物放出装置の製造
CA2134087C (en) * 1992-04-24 2007-07-17 Robert S. Ward Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range
US5614223A (en) * 1992-05-04 1997-03-25 Digestive Care Inc. Intraoral medicament-releasing device
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
DE69425781T2 (de) * 1993-06-11 2001-01-04 Nippon Chemi-Con Corp., Ome Understützungs- und Verbindungsgerät für einen Magnetfeldmodulationskopf, der in einer photomagnetischen Aufzeichnung benutzt wird
US5354835A (en) 1993-07-23 1994-10-11 Saudi Basic Industries Corporation Desalination process
JPH0797338A (ja) * 1993-09-20 1995-04-11 Shiseido Co Ltd 徐放性製剤
JPH07252166A (ja) * 1993-09-20 1995-10-03 Shiseido Co Ltd 徐放性製剤
KR950007873A (ko) 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
CA2264562C (en) * 1996-08-30 2012-01-03 Peptech Limited Sustained peptide-release formulation
US5945128A (en) * 1996-09-04 1999-08-31 Romano Deghenghi Process to manufacture implants containing bioactive peptides
AUPO251096A0 (en) 1996-09-23 1996-10-17 Cardiac Crc Nominees Pty Limited Polysiloxane-containing polyurethane elastomeric compositions
US5756127A (en) * 1996-10-29 1998-05-26 Wright Medical Technology, Inc. Implantable bioresorbable string of calcium sulfate beads
EP0996459B1 (en) * 1997-01-07 2005-09-21 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US5854127A (en) * 1997-03-13 1998-12-29 Micron Technology, Inc. Method of forming a contact landing pad
FI971385A0 (fi) 1997-04-04 1997-04-04 Bioxid Oy Biokompatibel komposition, metoder foer dess framstaellning samt anvaendning daerav
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7157555B1 (en) * 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US7220721B1 (en) * 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US6822016B2 (en) * 2001-09-10 2004-11-23 Johnson & Johnson Vision Care, Inc. Biomedical devices containing internal wetting agents
WO2000004037A1 (en) * 1998-07-14 2000-01-27 Amylin Pharmaceuticals, Inc. Uncoupling protein 4 (ucp-4) and methods of use
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
US20040071736A1 (en) * 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
US7259136B2 (en) * 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
DK1143989T3 (da) * 1999-01-14 2007-04-16 Amylin Pharmaceuticals Inc Exendiner til glucagonundertrykkelse
AU757605B2 (en) 1999-01-28 2003-02-27 Indevus Pharmaceuticals, Inc. Hydrogel compositions useful for the sustained release of macromolecules and methods of making same
CA2396157A1 (en) * 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
MXPA02009031A (es) * 2000-03-14 2004-08-19 Amylin Pharmaceuticals Inc Efectos del peptido-1(7-36) tipo glucagon en la motilidad antro-piloro.duodenal.
US6969480B2 (en) * 2000-05-12 2005-11-29 Matregen Corp. Method of producing structures using centrifugal forces
ATE397938T1 (de) * 2000-05-19 2008-07-15 Amylin Pharmaceuticals Inc Behandlung des akuten koronaren syndroms mit glp- 1
JP3498041B2 (ja) * 2000-05-29 2004-02-16 科研製薬株式会社 プラルモレリン含有点鼻用製剤
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
US8273713B2 (en) * 2000-12-14 2012-09-25 Amylin Pharmaceuticals, Llc Methods of treating obesity using PYY[3-36]
AU2002251448A1 (en) 2001-04-01 2002-10-15 Yeda Research And Development Co. Ltd. Weizmann Institute Of Science Oral absorbed drugs
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
DE10208335A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
ATE494002T1 (de) * 2002-06-14 2011-01-15 Amylin Pharmaceuticals Inc Prävention und/oder behandlung von colitis ulcerosa mit pyy oder pyyä3-36ü
US6942264B1 (en) * 2003-02-10 2005-09-13 Richard Mendez Disposable pet waste receptacle
CA2437639C (en) * 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
WO2005041873A2 (en) 2003-10-24 2005-05-12 Azopax Therapeutics Llc Formulation of exendin-4
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP1773293B1 (en) * 2004-06-17 2015-04-15 Endo Pharmaceuticals Solutions Inc. Compositions and methods for treating central precocious puberty
SE0402345L (sv) * 2004-09-24 2006-03-25 Mederio Ag Uppmätt läkemedelsdos
EP2455072A1 (en) * 2005-03-11 2012-05-23 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
US20070037897A1 (en) * 2005-08-12 2007-02-15 Guigui Wang Method for making contact lenses
JP2009507050A (ja) 2005-09-08 2009-02-19 ガストロテック・ファルマ・アクティーゼルスカブ 胆道ジスキネジーおよび／または胆道痛／不快の治療のためのｇｌｐ−１分子の使用
WO2008061355A1 (en) 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
MX2009011641A (es) * 2007-04-27 2010-03-04 Endo Pharmaceuticals Solutions Agentes de liberacion para dispositivo de implante y metodos para utilizar los mismos.
UA104866C2 (uk) * 2008-06-25 2014-03-25 Ендо Фармас'Ютікалз Солюшнз Інк. Імплантат октреотиду, який містить вивільняючу речовину

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876761A (en) * 1989-07-07 1999-03-02 Novartis Ag Sustained release formulations of water soluble peptides
WO2002049573A2 (en) * 2000-12-18 2002-06-27 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds

Also Published As

Publication number Publication date
EA015793B1 (ru) 2011-12-30
US20090087470A1 (en) 2009-04-02
AU2011201460A1 (en) 2011-04-21
CA2601304A1 (en) 2006-09-21
US7452868B2 (en) 2008-11-18
EP1888043A4 (en) 2010-07-28
US20250255936A1 (en) 2025-08-14
EA200701956A1 (ru) 2008-02-28
KR101399911B1 (ko) 2014-06-19
AU2011201457B2 (en) 2011-05-19
AU2006223161A1 (en) 2006-09-21
JP2008533046A (ja) 2008-08-21
WO2006099288A2 (en) 2006-09-21
CA2601304C (en) 2010-08-17
US20200353055A1 (en) 2020-11-12
WO2006099288A3 (en) 2007-03-01
US8507432B2 (en) 2013-08-13
NZ561400A (en) 2010-02-26
AU2011201460B2 (en) 2011-07-28
KR20080005496A (ko) 2008-01-14
IL185800A0 (en) 2008-01-06
CN103550137B (zh) 2015-07-29
AU2011201457A1 (en) 2011-04-21
CN101193626A (zh) 2008-06-04
US20200046806A1 (en) 2020-02-13
EP1888043A2 (en) 2008-02-20
JP4584331B2 (ja) 2010-11-17
JP2010189401A (ja) 2010-09-02
US20110009338A1 (en) 2011-01-13
EP2457564A1 (en) 2012-05-30
EP2455072A1 (en) 2012-05-23
CN103550137A (zh) 2014-02-05
US20060204540A1 (en) 2006-09-14
IL214617A0 (en) 2011-09-27
NO20074628L (no) 2007-11-27
US20170100461A1 (en) 2017-04-13
AU2011201471B2 (en) 2011-05-19
AU2011201471A1 (en) 2011-04-21
UA89398C2 (uk) 2010-01-25
IL214617A (en) 2016-05-31
US20100317579A1 (en) 2010-12-16
US7803773B2 (en) 2010-09-28

Similar Documents

Publication Publication Date Title
US20250255936A1 (en) Controlled release formulations of octreotide
US20190388500A1 (en) Delivery of dry formulations of octreotide
EP2317975B1 (en) Octreotide implant having a release agent
US20250249067A1 (en) Delivery of dry formulations of octreotide
HK1158491B (en) Octreotide implant having a release agent

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired